Lakefront Biotherapeutics NV (LTS:0JXZ)
€ 23.87 -0.060 (-0.25%) Market Cap: 1.57 Bil Enterprise Value: -664.17 Mil PE Ratio: 2.65 PB Ratio: 0.48 GF Score: 51/100

Lakefront Biotherapeutics NV at Morgan Stanley Global Healthcare Conference Transcript

Sep 15, 2026 / 09:35PM GMT
Release Date Price: €23.93 (+2.18%)
Judah Frommer
Morgan Stanley & Co Ltd - Analyst

All right. Good afternoon, everyone. Welcome to the final fireside of day 2 at Morgan Stanley's Global Healthcare Conference. I'm Judah Frommer, one of the SMid biotech analysts here. We're very excited to have Henry, Aaron, and Eric representing Lakefront.

Let me just get through a quick disclosure before we get started. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com/researchdisclosures.

Questions & Answers

Judah Frommer
Morgan Stanley & Co Ltd - Analyst

All right. With that, the team's been leading Lakefront through quite a transformation. So before we dive in, maybe give the audience an intro to the company and your focus since taking the helm last summer.

Henry Gosebruch
Lakefront Biotherapeutics NV - Chief Executive Officer, Executive Director

Great. Well, we're delighted to be here

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot